Monday, December 22, 2014

Considerations for conducting trials in low-cost countries

Rick Morrison, Founder and CEO of Comprehend Systems recently took and in-depth look at some of the major considerations an company should look at before they venture into low-cost countries for clinical trials.  With the steep cost of clinical trials - Astra Zeneca faced a cost of $11.7 billion for each of the five drugs it brought to market from 2007-2011 - it's important that companies find efficient, low cost and ethical ways to bring drugs to market faster and safer.

Morrison suggests looking into expanding clinical trials beyond domestic trials to reap the benefits of diverse patient populations, the shrinking of cost and time to market for successful drugs and the ability to test the products in the countries and patient populations to which they'll be sold.    Not only are these benefits clear within themselves but the number of patients presented in a global clinical trial allows to companies to bring drugs to market an average of 6-7 months faster.

What are some of the benefits you see from expanding clinical trials beyond the traditional borders?

This April at Partnership in Clinical Trials, we will host Effects of Globalization on Clinical Development a full day workshop to kick off the 2015 event.  Presentations will look at global data, streamlining outsourcing, patient recruitment and more.  For more information on this session and the rest of the program, download the agenda.  As a reader of this blog, when you register to join us and mention code XP2000BL, you can save $100 off the current rate.  We're also giving away a few free passes on Twitter.  Find out how you can win.

No comments: